These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 21610148)

  • 1. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
    Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
    Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
    LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
    Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
    Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
    Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
    Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
    Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters.
    Chandra V; Das T; Gulati P; Biswas NK; Rote S; Chatterjee U; Ghosh SN; Deb S; Saha SK; Chowdhury AK; Ghosh S; Rudin CM; Mukherjee A; Basu A; Dhara S
    PLoS One; 2015; 10(3):e0116390. PubMed ID: 25775002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation.
    Antonucci L; Di Magno L; D'Amico D; Manni S; Serrao SM; Di Pastena F; Bordone R; Yurtsever ZN; Caimano M; Petroni M; Giorgi A; Schininà ME; Yates Iii JR; Di Marcotullio L; De Smaele E; Checquolo S; Capalbo C; Agostinelli E; Maroder M; Coni S; Canettieri G
    Int J Oncol; 2019 Feb; 54(2):505-514. PubMed ID: 30483764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
    Kogame A; Tagawa Y; Shibata S; Tojo H; Miyamoto M; Tohyama K; Kondo T; Prakash S; Shyu WC; Asahi S
    Drug Metab Dispos; 2013 Apr; 41(4):727-34. PubMed ID: 23298863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and preclinical development of vismodegib.
    Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
    Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Hedgehog pathway in cancer: can the spines be smoothened?
    Ailles L; Siu LL
    Clin Cancer Res; 2011 Apr; 17(8):2071-3. PubMed ID: 21367749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
    Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
    Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
    Wang F; Jiang H; Deng Y; Yu J; Zhan M; Zhao L; Chen Y
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2399-2402. PubMed ID: 29929879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
    Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
    Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.